Is long-term monitoring required after treatment with gosatuzumab (Todavi)?

Gosatuzumab (Trodelvy) is an antibody-drug conjugate (ADC) that targets < span>Trop-2protein and carries topoisomeraseIinhibitorSN-38 as a cytotoxic payload. It is primarily used to treat triple-negative breast cancer (TNBC) and certain types of advanced urothelial cancer. Because its mechanism of action involves chemotherapy components, patients require long-term monitoring during and after treatment to ensure efficacy and manage potential adverse reactions.

Gosatuzumab may cause severe myelosuppression, particularly neutropenia and anemia. Therefore, regular blood routine monitoring is required during treatment to detect and manage leukopenia in a timely manner, and adjust the dose or delay administration if necessary. In addition, patients may still experience delayed effects of myelosuppression after treatment ends, and therefore require continued follow-up to reduce the risk of infection.

This drug often causes serious gastrointestinal adverse effects, especially diarrhea, which may lead to dehydration and electrolyte imbalance. Therefore, patients should be closely monitored for intestinal reactions during and after treatment and given antidiarrheal medications, electrolyte replacement, or intravenous fluid support as needed. Long-term monitoring is particularly important for patients with a history of chronic gastrointestinal disease to prevent complications.

Because gosatuzumab is a cytotoxic drug, it may have certain effects on liver and kidney function. Therefore, patients need regular liver and kidney function tests after treatment to assess organ damage. In addition, for the overall health status of patients with advanced cancer, long-term follow-up also includes disease progression monitoring, imaging examinations, and psychological support to optimize treatment strategies and improve quality of life.

Reference materials:https://www.trodelvy.com/